April 28 (Reuters) - Trillium Therapeutics Inc TRIL.TO :
* TRILLIUM THERAPEUTICS INC - TTI-622 MONOTHERAPY SHOWS 33% OBJECTIVE RESPONSE RATE (ORR) IN RELAPSED/REFRACTORY (R/R) LYMPHOMAS AT 0.8-18 MG/KG DOSES
* TRILLIUM THERAPEUTICS INC - TTI-621 MONOTHERAPY SHOWS 18-29% ORR IN R/R T- AND B-CELL LYMPHOMAS AT 0.2-2.0 MG/KG DOSES
* TRILLIUM THERAPEUTICS INC - TTI-622 AND TTI-621 HAVE BEEN WELL TOLERATED AT DOSES UP TO 18 MG/KG AND 2.0 MG/KG WEEKLY, RESPECTIVELY